Background: Reliable insulin delivery is critical in the management of type 1 diabetes. Limitations of insulin pump therapy (IPT) are the maximum cannula life of three days, and a reported failure rate of 15-25% prior to this, which may impact glycemia and quality of life.

Objective: We aimed to determine the feasibility of a prototype cannula for an extended wear infusion set.

Materials and Methods: CapBio’s SteadiFlow technology (Capillary Biomedical, Irvine, CA, USA) consists of a cannula with a soft outer polymer reinforced by an internal metal coil to prevent kinking and three additional side ports to reduce the risk of cannula blockages. Adults with type 1 diabetes using IPT participated in a study with three study periods. For each period a new infusion set was inserted for an intended wear of 7 days. During Period 1 saline was infused via the investigational set through an additional insulin pump. During Periods 2 and 3 insulin lispro was delivered via the investigational set connected to the participant’s own insulin pump. Results are expressed as mean (SD).

Results: Twenty participants (Medtronic 640G [n=11]; 670G [n=3]; Tandem t-slim X2 [n=6]) with type 1 diabetes (age 44Y [14]; HbA1c 7.3% [0.6]/56mmol/mol [6]; female 50%) were studied. The 7-day survival rates of the prototype cannula set were 19/20 (95%) for period one and 36/41(88%) for periods two and three combined. No serious adverse events were reported. Mild infusion site reactions occurred in 7 participants. Hyperglycemia was reported as an adverse event in 7 participants resulting in premature cannula removal in 4 cases (occurring, respectively, on Days 1, 2, 5, and 6 during Weeks 2 or 3). Infusion site infection caused the 5th premature removal (on Day 3). Post-removal, no kinked cannulas were observed.

Conclusions: These study results confirm the feasibility of the extended-life investigational cannula. Larger, randomised studies are required to confirm these preliminary observations.

Disclosure

D. N. O’neal: Advisory Panel; Self; Abbott Diabetes, Medtronic, Sanofi, Research Support; Self; Dexcom, Inc., GlySens Incorporated, Medtronic, Pacific Diabetes Technologies. N. Venkatesh: None. K. Brown: None. E. I. Ekinci: None. S. Fourlanos: Advisory Panel; Self; Pfizer Foundation, Speaker’s Bureau; Self; AstraZeneca, Eli Lilly and Company. J. R. Kastner: None. R. Macisaac: Advisory Panel; Self; AstraZeneca, Bayer Healthcare Pharmaceuticals Inc., Novo Nordisk, Servier Laboratories, Speaker’s Bureau; Self; Boehringer Ingelheim International GmbH, Novo Nordisk. D. B. Muchmore: Consultant; Self; Capillary Biomedical, Inc., Diasome Pharmaceuticals, Inc., Zucara Therapeutics Inc., Stock/Shareholder; Self; Capillary Biomedical, Inc., Diasome Pharmaceuticals, Inc.

© 2021 by the American Diabetes Association
2021
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.